Stock UCBUCB
Add to a list
To use this feature you must be a member
Log inSign up

UCB Stock

Equities

UCB

BE0003739530

Pharmaceuticals

Real-time Euronext Bruxelles
Other stock markets
 12:28:43 14/07/2025 +04 		5-day change 1st Jan Change
169.20 EUR -1.02% Intraday chart for UCB -0.41% -11.97%
07-01 Alvotech, Advanz Pharma Sign Supply, Commercial Deal for Cimzia Biosimilar in Europe MT
06-27 UCB Announces Positive Results from GEMZ Phase 3 Study of Fenfluramine in CDKL5 Deficiency Disorder CI

Valuation: UCB

Capitalization 32.49B 37.99B 30.26B 28.15B 52.01B 3,260B 57.79B 363B 139B 1,526B 142B 140B 5,599B P/E ratio 2025 *
32.6x
P/E ratio 2026 * 23.6x
Enterprise value 33.1B 38.7B 30.83B 28.67B 52.98B 3,321B 58.88B 369B 141B 1,555B 145B 142B 5,703B EV / Sales 2025 *
4.92x
EV / Sales 2026 * 4.16x
Free-Float
61.3%
Yield 2025 *
0.83%
Yield 2026 * 0.85%
More valuation ratios * Estimated data

Chart: UCB

Dynamic Chart

Latest news: UCB

Alvotech, Advanz Pharma Sign Supply, Commercial Deal for Cimzia Biosimilar in Europe 07-01 MT
UCB Announces Positive Results from GEMZ Phase 3 Study of Fenfluramine in CDKL5 Deficiency Disorder 06-27 CI
UCB: share up after positive phase 3 trial 06-27 CF
EU reviews risk of abuse in some treatments for alcohol dependency (June 20) 06-23 RE
Europe stocks fall on fears of Iranian retaliation after U.S. strikes 06-23 RE
Europe stocks fall on fears of Iranian retaliation after U.S. strikes 06-23 RE
Morgan Stanley Upgrades UCB to Overweight, Raises PT 06-23 MT
UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity 06-12 CI
UCB Announces New Biologics Manufacturing Facility In U.S. 06-12 RE
Biogen, UCB Say Dapirolizumab Pegol Phase 3 Study Shows Improvement in Fatigue, Reduction in Disease Activity 06-12 MT
UCB and Biogen Inc. Announces Results from Phase 3 PHOENYCS GO Study Evaluating Dapirolizumab Pegol in Systemic Lupus Erythematosus 06-12 CI
UCB Says Its DZP Shows 'Efficacy' Across Multiple Clinical Endpoints 06-12 RE
BIMZELX® (bimekizumab-bkzx) Three-Year Data at EULAR 2025 Showed Lasting Efficacy and Control of Inflammation in Psoriatic Arthritis and Axial Spondyloarthritis by UCB 06-11 CI
More news

Last Transcript: UCB

Logo UCB
UCB SA, 2024 Earnings Call, Feb 27, 2025
02-27
More transcripts

Analysts' recommendations: UCB

Morgan Stanley Upgrades UCB to Overweight, Raises PT 06-23 MT
Intron Health Begins UCB's Coverage at Buy 06-11 MT
Sadif Investment Analytics Downgrades UCB to Sell 05-30 MT
UCB : UCB finally becomes affordable 04-14Alphavalue
UCB : Lower-than-expected 2025 guidance weighed on good H2 24 results 02-28Alphavalue
More recommendations

Press Releases: UCB

UCB : Transparency notification FMR LLC 07-10 PU
UCB : Transparency notification BlackRock, Inc. 07-08 PU
UCB : BIMZELX(bimekizumab-bkzx) two-year data at AAD showed potential to eliminate draining tunnels in hidradenitis suppurativa (HS), and reduction in disease burden 07-08 PU
UCB : presents latest research advancements at European Pediatric Neurology Society Congress 07-08 PU
UCB : announces positive results from GEMZ phase 3 study of fenfluramine in CDKL5 Deficiency Disorder 06-27 PU
More press releases

News in other languages: UCB

Prima beursdebuut voor EnergyVision in rustige beursweek 07-13
Wall Street vue dans le vert, les négociations commerciales continuent 07-09
Succesvolle IPO EnergyVision op lichtgroene beurs 07-09
Le secteur pharmaceutique européen recule après des menaces douanières de Trump 07-09
Umicore smaakmaker in Brussel 07-06
More news

Quotes and Performance

1 day-1.02%
1 week-0.41%
Current month+1.35%
1 month+4.48%
3 months+21.64%
6 months-10.64%
Current year-11.97%
More quotes

Course Extremes

1 week 165.1
Extreme 165.1
 174.3
1 month 153.65
Extreme 153.65
 174.3
Current year 129.35
Extreme 129.35
 198.95
1 year 129.35
Extreme 129.35
 198.95
3 years 65.4
Extreme 65.4
 198.95
5 years 65.4
Extreme 65.4
 198.95
10 years 54.84
Extreme 54.84
 198.95
More quotes

Managers and Directors: UCB

Manager TitleAgeSince
Jean-Christophe Tellier CEO
 Chief Executive Officer 66 01/01/2015
Sandrine Dufour DFI
 Director of Finance/CFO 58 01/07/2020
Antje Witte IRC
 Investor Relations Contact - -
Director TitleAgeSince
Charles-Antoine Janssen BRD
 Director/Board Member 54 01/01/2012
Jean-Christophe Tellier BRD
 Director/Board Member 66 01/01/2015
Jonkheer Cédric van Rijckevorsel BRD
 Director/Board Member 55 24/04/2014
More insiders

Biopharmaceuticals

Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi.($)
UCB Stock UCB
-1.02%-0.41%+17.62%+107.00% 37.99B
CSL LIMITED Stock CSL Limited
+0.28%-2.57%-21.70%-18.43% 76.69B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.43%+3.72%-48.39%-5.69% 59.99B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
-2.13%+5.70%+28.43%+27.04% 54.72B
BIOGEN INC. Stock Biogen Inc.
-0.83%+1.01%-41.66%-37.44% 19.67B
INNOVENT BIOLOGICS, INC. Stock Innovent Biologics, Inc.
+1.80%-0.67%+109.72%+112.99% 17.54B
ALTEOGEN INC. Stock ALTEOGEN Inc.
-2.23%+16.91%+61.10%+725.71% 17.06B
INTRA-CELLULAR THERAPIES, INC. Stock Intra-Cellular Therapies, Inc.
-0.04%-.--%+68.78%+146.99% 14.02B
INCYTE CORPORATION Stock Incyte Corporation
-2.49%+0.20%+7.74%-13.63% 13.28B
MODERNA, INC. Stock Moderna, Inc.
-1.87%+10.33%-72.30%-80.36% 13.01B
Average -0.71%+1.72%+10.93%+96.42% 32.4B
Weighted average by Cap. -0.40%+1.52%-0.21%+56.34%
See all sector performances

Financials

2025 *2026 *
Net sales 6.73B 7.87B 6.27B 5.83B 10.77B 675B 11.97B 75.09B 28.71B 316B 29.51B 28.9B 1,159B 7.63B 8.93B 7.11B 6.61B 12.22B 766B 13.58B 85.21B 32.58B 359B 33.49B 32.8B 1,316B
Net income 964M 1.13B 898M 835M 1.54B 96.69B 1.71B 10.76B 4.11B 45.27B 4.23B 4.14B 166B 1.37B 1.61B 1.28B 1.19B 2.2B 138B 2.45B 15.34B 5.87B 64.58B 6.03B 5.9B 237B
Net Debt 608M 711M 567M 527M 974M 61.05B 1.08B 6.79B 2.6B 28.58B 2.67B 2.61B 105B -743M -869M -692M -644M -1.19B -74.58B -1.32B -8.3B -3.17B -34.92B -3.26B -3.19B -128B
More financial data * Estimated data

Company Profile

Logo UCB
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
Employees
9,215
Sector
Pharmaceuticals
Calendar
07-31 - Q2 2025 Earnings Release
More about the company

Quotes

Date Price Change Volume
14/07/25 169.20 € -1.02% 17,981
11/07/25 170.95 € -0.96% 197,580
10/07/25 172.60 € +1.35% 238,735
09/07/25 170.30 € +0.12% 207,080
08/07/25 170.10 € +0.12% 239,510

Real-time Euronext Bruxelles, July 14, 2025 at 12:28 pm

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating
Investor Rating
ESG MSCI
AA
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
170.95EUR
Average target price
212.29EUR
Spread / Average Target
+24.18%
Consensus
EPS Estimates
Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. UCB Stock

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States
United-States
Canada
Canada

MIDDLE EAST

Saudi Arabia
Saudi Arabia
United Arab Emirates
United Arab Emirates

EUROPE

France
France
Deutschland
Deutschland
Suisse
Suisse
Schweiz
Schweiz
Italia
Italia
Österreich
Österreich
België
België
Nederland
Nederland
España
España
Sverige
Sverige
United Kingdom
United Kingdom

APAC

Australia
Australia
India
India
Hong Kong
Hong Kong
United States

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition